-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

Benzinga·01/21/2026 17:59:22
Listen to the news
Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $15 to $32.